In situ protection against islet allograft rejection by CTLA4Ig transduction

Transplantation

Volumn 90, Issue 9, 2010, Pages 951-957

  Londrigan, Sarah L ^a,b   Sutherland, Robyn M ^a   Brady, Jamie L ^a   Carrington, Emma M ^a   Cowan, Peter J ^b,c   D'Apice, Anthony J F ^b,c   O'Connell, Philip J ^d   Zhan, Yifan ^a   Lew, Andrew M ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Allograft; Costimulation; Islet transplantation; Local immunosuppression

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; ENZYME IMMUNOASSAY; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CAPSULE; MOUSE; NONHUMAN; PANCREAS ISLET GRAFT REJECTION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650286569     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f54728     Document Type: Article

References (55)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free im-munosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Hirshberg B, Rother KI, Harlan DM. Islet transplantation: Where do we stand now? Diabetes Metab Res Rev 2003; 19: 175.
3. Londrigan SL, Brady JL, Sutherland RM, et al. Evaluation of promoters for driving efficient transgene expression in neonatal porcine islets. Xenotransplantation 2007; 14: 119.
4. Londrigan SL, Sutherland RM, Brady JL, et al. Prolonged local expression of anti-CD4 antibody by adenovirally transduced allografts can promote long-term graft survival. J Gene Med 2006; 8: 42.
5. Csete ME, Benhamou PY, Drazan KE, et al. Efficient gene transfer to pancreatic islets mediated by adenoviral vectors. Transplantation 1995; 59: 263.
6. Grey ST, Arvelo MB, Hasenkamp WM, et al. Adenovirus-mediated gene transfer of the anti-apoptotic protein A20 in rodent islets inhibits IL-1 beta-induced NO release. Transplant Proc 1999; 31: 789.
7. Sigalla J, David A, Anegon I, et al. Adenovirus-mediated gene transfer into isolated mouse adult pancreatic islets: Normal beta-cell function despite induction of an anti-adenovirus immune response. Hum Gene Ther 1997; 8: 1625.
8. Akamaru Y, Ito T, Uchikoshi F, et al. Ex vivo and systemic transfer of adenovirus-mediated CTLA4Ig gene combined with a short course of FK506 therapy prolongs islet graft survival. Transpl Immunol 2003; 11: 91.
9. Feng S, Quickel RR, Hollister-Lock J, et al. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig. Transplantation 1999; 67: 1607.
10. Jin YZ, Xie SS. Bicistronic adenovirus-mediated gene transfer of CTLA4Ig gene and CD40Ig gene result in indefinite survival of islet xenograft. Transplant Proc 2003; 35: 3165.
11. Laumonier T, Potiron N, Boeffard F, et al. CTLA4Ig adenoviral gene transfer induces long-term islet rat allograft survival, without tolerance, after systemic but not local intragraft expression. Hum Gene Ther 2003; 14: 561.
12. Potiron N, Chagneau C, Boeffard F, et al. Adenovirus-mediated CTLA4Ig or CD40Ig gene transfer delays pancreatic islet rejection in a rat-to-mouse xenotransplantation model after systemic but not local expression. Cell Transplant 2005; 14: 263.
13. Thummala NR, Ghosh SS, Lee SW, et al. A non-immunogenic adeno-viral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphospho- glucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Ther 2002; 9: 981.
14. Wang G, Feng Y, Hao J, et al. Induction of xenogeneic islet transplantation tolerance by simultaneously blocking CD28-B7 and OX40-OX40L co-stimulatory pathways. Sci China C Life Sci 2005; 48: 515.
15. Wang GM, Yang Y, Jin YZ, et al. Blockade of both CD28/B7 and OX40/ OX40L co-stimulatory signal pathways prolongs the survival of islet xenografts. Transplant Proc 2005; 37: 4449.
16. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985.
17. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459.
18. Linsley PS, BradyW,UrnesM,etal. CTLA-4isasecond receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
19. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992; 257: 789.
20. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145.
21. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
22. Tran HM, Nickerson PW, Restifo AC, et al. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 1997; 159: 2232.
23. Durrbach A, Pestana JM, Pearson T, et al. A phase III Study of belata-cept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
24. Vincenti F, Charpentiet B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclo-sporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
25. Sutherland RM, Brady JL, Georgiou HM, et al. Protective effect of CTLA4Ig secreted by transgenic fetal pancreas allografts. Transplantation 2000; 69: 1806.
26. Sutherland RM, Allison J, Thomas HE, et al. Bcl-2 protection of islet allografts is unmasked by costimulation blockade. Transplantation 2004; 77: 1610.
27. Chahine AA, Yu M,McKernan M, et al. Local CTLA4Ig synergizes with one-dose anti-LFA-1 to achieve long-term acceptance of pancreatic islet allografts. Transplant Proc 1994; 26: 3296.
28. Chahine AA,YuM,McKernanMM,etal.Immunomodulationofpan-creatic islet allografts in mice with CTLA4Ig secreting muscle cells. Transplantation 1995; 59: 1313.
29. Steurer W, Nickerson PW, Steele AW, et al. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995; 155: 1165.
30. Gainer AL, Suarez-Pinzon WL, Min WP, et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998; 66: 194.
31. Miao G, Ito T, Uchikoshi F, et al. Development of donor-specific im-munoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. Transplantation 2004; 78: 59.
32. Baratin M, Bonin K, Daniel C. Frontline: Peripheral priming of allo-reactive T cells by the direct pathway of allorecognition. Eur J Immunol 2004; 34: 3305.
33. Zhou P, Hwang KW, Palucki D, et al. Secondary lymphoid organs are important but not absolutely required for allograft responses. Am J Transplant 2003; 3: 259.
34. Wakim LM, Gebhardt T, Heath WR, et al. Cutting edge: Local recall responses by memory T cells newly recruited to peripheral nonlym-phoid tissues. J Immunol 2008; 181: 5837.
35. Wakim LM, Waithman J, van Rooijen N, et al. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008; 319:198.
36. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004; 10: 927.
37. Gett AV, Hodgkin PD. A cellular calculus for signal integration by T cells. Nat Immunol 2000; 1: 239.
38. Lindstein T, June CH, Ledbetter JA, et al. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989; 244: 339.
39. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/ cytokines. Proc Natl Acad Sci USA 1989; 86: 1333.
40. David R, Ma L, Ivetic A, et al. T-cell receptor- and CD28-induced Vav1 activity is required for the accumulation of primed T cells into antigenic tissue. Blood 2009; 113: 3696.
41. Mirenda V, Jarmin SJ, David R, et al. Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 2007; 109: 2968.
42. Mellor AL, Baban B, Chandler P, et al. Cutting edge: Induced in-doleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171: 1652.
43. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097.
44. Guillot C, Menoret S, Guillonneau C, et al. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. Blood 2003; 101: 3325.
45. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 2006; 24: 233.
46. Zammit DJ, Cauley LS, Pham QM, et al. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005; 22: 561.
47. Boesteanu AC, Katsikis PD. Memory T cells need CD28 costimulation to remember. Semin Immunol 2009; 21: 69.
48. + T cells require CD28 costimulation. J Immunol 2007; 179: 6494.
49. Ndejembi MP, Teijaro JR, Patke DS, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006; 177: 7698.
50. + T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol 2008; 180: 1148.
51. Jiang Z, Feingold E, Kochanek S, et al. Systemic delivery of a high-capacity adenoviral vector expressing mouse CTLA4Ig improves skeletal muscle gene therapy. Mol Ther 2002; 6: 369.
52. Gong N, Pleyer U, Yang J, et al. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med 2006; 8: 459.
53. Mihara M, Tan I, Chuzhin Y, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000; 106: 91.
54. Sutherland RM, Mountford JN, Allison J, et al. The non-immune RIP-Kb mouse is a useful host for islet transplantation, as the diabetes is spontaneous, mild and predictable. IntJExp Diabetes Res 2002; 3:37.
55. Martin RM, Brady JL, Lew AM. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 1998; 212: 187.